News

May 28, 2020

Harro Höfliger and Vaxxas Announce Alliance to Develop Industrial‐scale Aseptic Processing Line for Vaccine Products Based on Vaxxas’ High Density Microarray Patch (HD‐MAP)

May 8, 2020

Urgent COVID-19 response package needed to support and protect $170b life sciences sector

March 24, 2020

Bill Ferris, pioneer venture capitalist, appointed Chair of the MRCF

March 18, 2020

Vaxxas High-Density Microarray Patch to Efficiently Deliver Vaccines Directly to Skin

March 18, 2020

Vaxxas Awarded US$5 million Grant for Clinical Study of Measles and Rubella Vaccination

March 10, 2020

Multi-million-dollar mission to tackle major global health challenges

December 16, 2019

MRCF establishes life science incubator to boost NZ startup successes

October 23, 2019

QUE Oncology recruiting Sydney breast cancer patients experiencing hot flushes & night sweats

September 26, 2019

$14m invested in University of Melbourne spin-out to create vaccine for periodontal gum disease

August 28, 2019

Perth tech joint-winner in global finals for international start-up competition

August 20, 2019

Q-Sera’s innovative blood clotting technology granted patent in US

August 1, 2019

QUE Oncology launches Phase II trials in New Zealand

July 29, 2019

QUE Oncology Appoints Dr. Julie Cherrington and Elizabeth Cermak to Board of Directors

July 23, 2019

PolyActiva completes recruitment in key Phase I glaucoma implant safety study.

May 22, 2019

Morphoseq™ at ‘Sequencing, Finishing and Analysis in the Future’ meeting, USA

May 16, 2019

Longas Launches, Unveiling Morphoseq™ Long Read DNA Sequencing Technology

May 1, 2019

Brandon Capital Partners launches new Medical Research Commercialisation Fund, seeks NZ institutional

April 2, 2019

QUE Oncology launches Phase II trials in the United States

March 15, 2019

MRCF launches Perth-based biotech developing new treatment for Cystic Fibrosis

February 25, 2019

Aravax reveals positive Phase I trial results at world-leading allergy conference

January 31, 2019

Australian Phase II trial commences for potential world-first treatment of viral conjunctivitis

December 3, 2018

Perth tech takes out Australian start-up competition to join international finals

November 21, 2018

The WILD Program launches within the Victorian STEM sector, with first intake of 20 women

October 2, 2018

QUE Oncology launches Phase II trials

August 31, 2018

PolyActiva commences first Phase I clinical trial with potential to improve lives of millions

August 14, 2018

Paragen Bio launches in northern Queensland with $6 million investment

June 4, 2018

MRCF announces largest investment to date by Biotechnology Translation Fund

February 28, 2018

MRCF invests in San Diego ophthalmic biotech company, clinical trials to take place in Australia

February 19, 2018

Australian biotech company launched with AU$7m investment to develop therapies for treating obesity

February 13, 2018

Auspherix Awarded Innovate UK Grant to Treat Life-threatening Respiratory Infections

December 13, 2017

New Zealand biomedical discovery set to revolutionise the global pain relief drug market

November 27, 2017

Q-Sera’s innovative blood clotting technology patent granted in China

November 11, 2017

Australian investors lead AU$60m raise to develop new technology

November 3, 2017

Osprey Medical and AKI highlighted at largest international cardiovascular conference TCT 2017

October 23, 2017

Q-Sera’s ground-breaking blood clotting technology presented at leading scientific conference in South Africa

May 29, 2020

May 28, 2020

May 8, 2020

March 24, 2020

March 18, 2020

March 18, 2020

March 10, 2020

December 16, 2019

October 23, 2019

September 26, 2019

August 28, 2019

August 20, 2019

August 1, 2019

July 29, 2019

July 23, 2019

May 22, 2019

May 16, 2019

May 1, 2019

April 2, 2019

March 15, 2019

February 25, 2019

January 31, 2019

December 3, 2018

November 21, 2018

October 2, 2018

August 31, 2018

August 14, 2018

June 4, 2018

February 28, 2018

February 19, 2018

February 13, 2018

December 13, 2017

November 27, 2017

November 11, 2017

November 3, 2017

October 23, 2017

Contact

Brandon Capital Partners Pty Ltd manages the MRCF Collaboration.

Melbourne

Sydney

For media inquiries